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Abstract 
Background: CCR5-using (r5) HIV-1 predominates during asymptomatic disease followed by occasional emergence 
of CXCR4-using (x4) or dual tropic (r5x4) virus. We examined the contribution of the x4 and r5 components to replica-
tive fitness of HIV-1 isolates.
Methods: Dual tropic r5x4 viruses were predicted from average HIV-1 env sequences of two primary subtype C 
HIV-1 isolates (C19 and C27) and from two patient plasma samples (B12 and B19). Chimeric Env viruses with an NL4-3 
backbone were constructed from the B12 and B19 env sequences. To determine replicative fitness, these primary and 
chimeric dual tropic HIV-1 were then competed against HIV-1 reference isolates in U87.CD4 cells expressing CXCR4 or 
CCR5 or in PBMCs ± entry inhibitors. Contribution of the x4 and r5 clones within the quasispecies of these chimeric or 
primary HIV-1 isolates were then compared to the frequency of x4, r5, and dual tropic clones within the quasispecies 
as predicted by phenotypic assays, clonal sequencing, and 454 deep sequencing.
Results: In the primary HIV-1 isolates (C19 and C27), subtype C dual tropic clones dominated over x4 clones while 
pure r5 clones were absent. In two subtype B chimeric viruses (B12 and B19), r5 clones were >100-fold more abun-
dant than x4 or r5/x4 clones. The dual tropic C19 and C27 HIV-1 isolates outcompeted r5 primary HIV-1 isolates, B2 
and C3 in PBMCs. When AMD3100 was added or when only U87.CD4.CCR5 cells were used, the B2 and C3 reference 
viruses now out-competed the r5 component of the dual tropic C19 and C27. In contrast, the same replicative fitness 
was observed with dualtropic B12 and B19 HIV-1 isolates relative to x4 HIV-1 A8 and E6 or the r5 B2 and C3 viruses, 
even when the r5 or x4 component was inhibited by maraviroc (or AMD3100) or in U87.CD4.CXCR4 (or CCR5) cells.
Conclusions: In the dual tropic HIV-1 isolates, the x4 replicative fitness is higher than r5 clones but the x4 or x4/
r5 clones are typically at low frequency in the intrapatient virus population. Ex vivo HIV propagation promotes 
outgrowth of the x4 clones and provides an over-estimate of x4 dominance in replicative fitness within dual tropic 
viruses.
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Background
Human immunodeficiency virus entry into host cells 
involves binding to CD4 and one of two coreceptors, 
namely CCR5 and CXCR4, hence the two viral pheno-
types, the r5- and x4-using viruses. CCR5 is expressed 
in conjunction with surface CD4 on activated lympho-
cytes, macrophages, dendritic cells, and brain cells, while 
CXCR4 with CD4 are found on the surface of resting T 
cells and monocytes [1–3]. Although other chemokine 
receptors can mediate low level HIV-1 entry [4, 5], CCR5 
and CXCR4 remain the primary co-receptors for all 
diverse HIV-1 subtypes as well as other primary lentivi-
ruses, e.g. HIV-2, simian immunodeficiency virus from 
chimpanzees, sooty mangabeys, and African green mon-
keys [6–9]. The r5 HIV-1 variants are preferentially trans-
mitted and predominate during the asymptomatic period 
of infection whereas x4 HIV-1 emerges late in disease 
and in less than 50 % of patients [10–13].
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HIV-1 entry into host cells is almost exclusively trig-
gered by Env glycoproteins. In fact, expression of only 
HIV-1 Env in an effector cell can mediate fusion with a 
target cell expressing CD4 and a co-receptor (reviewed 
in [14]). During virus assembly, the Env gp160 precursor 
is cleaved by cellular proteases into the membrane span-
ning gp41 and the soluble gp120 subunits, which remain 
covalently linked through a disulfide bridge [15]. On the 
virus particle, Env gp120/gp41 form trimer spikes that 
mediate virus attachment to the receptor complex on 
the cell surface (reviewed in [14]). First, a conserved C4 
region in gp120 interacts with the amino-terminal extra-
cellular immunoglobulin-like domain of the CD4 recep-
tor. Upon interaction with CD4, the V3 loop of gp120 
can engage the second extracellular loop of CCR5 (or 
CXCR4) while a gp120 conformational change exposes a 
second Env site (comprised in part by the C2 region) to 
bind with the N terminus of the co-receptor.
Although the V3 loop appears to define selective bind-
ing of either CCR5 or CXCR4, specificity for a particu-
lar co-receptor also appears to extend to other regions 
throughout gp120 [16–18]. Specifically, the V1/V2 loops 
on HIV-1 gp120 can influence co-receptor usage but 
not as efficiently as the V3 domain [19–21]. Differential 
interaction with the co-receptors may be related to the 
higher negative charge of the second extracellular loop 
of CXCR4 compared to that of CCR5, which may in turn 
favor binding to a more positively charged gp120 V3 loop 
[22, 23]. Several algorithms/models have been devel-
oped to predict HIV-1 co-receptor usage from the amino 
sequence in Env. Geno2Pheno and PSSM are algorithms 
based solely on the V3 loop sequence and are generally 
greater than 85  % accurate in predicting co-receptor 
usage by HIV-1 subtype B strains [24–27]. Both of these 
models are heavily weighted by positive charges at amino 
acid positions 11 and/or 25 in the V3 loop, which are 
nearly absolute in predicting CXCR4 usage. In addition, 
Phenoseq a new program has the ability to predict core-
ceptor usage for all the major subtypes.
The switch from r5 to x4 virus has been associated with 
rapid depletion of CD4+ T cells [28, 29]. Patients harbor-
ing x4 viruses progress to AIDS more rapidly than those 
harboring exclusively r5 viruses implying that CXCR4 
utilization is linked to a stronger pathogenic phenotype 
and a switch to CXCR4 utilization is a causative factor in 
disease progression, this has been mainly studied in sub-
type B [28, 30, 31]. However, this hypothesis is quite con-
troversial considering that CD4 cell decline is observed in 
nearly all HIV-infected patients despite the fact that only 
50 % switch from r5 to x4 viruses and only late in disease 
among subtype B individuals. A switch in coreceptor 
usage rarely occurs in subtype C. Three main hypotheses 
for the switch in coreceptor usage have been proposed. 
The transmission-mutation hypothesis proposes that 
predominance of r5 viruses during transmission and 
early infection is due to active selection of r5 and that the 
coreceptor switch is a result of virus evolution during the 
course of disease [29]. The target cell-based hypothesis 
is based on the inability of quiescent, naïve CXCR4+/
CD4+ T cells to support HIV-1 replication whereas the 
memory CCR5+/CD4+ T cells are activated at a higher 
frequency and as such, support greater HIV-1 replica-
tion [32, 33]. With the depletion of the memory T cell 
population, there would be a shift in cells that support x4 
versus r5 replication. Finally, the immune-control hypoth-
esis assumes that x4 viruses are recognized better by the 
immune system than r5 viruses [34, 35]. Thus, x4 viruses 
would only emerge later in infection due in part to poor 
virologic control by a dysfunctional immune response. 
This hypothesis also suggests that emergence of x4 over r5 
variants relates to higher replicative fitness [36]. However, 
increased sensitivity of CXCR4-using virus compared to 
CCR5-using virus to autologous neutralizing antibodies is 
not supported by other studies [37].
These hypotheses generally focus on the displacement 
of r5 HIV-1 by x4 HIV-1 late in disease progression but 
do not necessarily account for dual tropic HIV-1 variants. 
An HIV-1 isolate that utilizes both CCR5 and CXCR4 
for entry is commonly referred to as dual tropic (r5x4). 
However, the intrapatient dual/mixed (dm) may be any 
combination of HIV-1 clones using just CCR5 or CXCR4 
for entry (x4 or r5 HIV-1) in addition to clones capable of 
infecting both CD4+/CCR5+ and CD4+/CXCR4+ cells 
(r5x4 HIV-1). The contribution of the r5, x4, and r5x4 to 
the replicative fitness of an HIV-1 isolate is poorly under-
stood but could be consequential to disease progression. 
Dominance of pure x4 variants within the intrapatient 
HIV-1 population at any time, even in late disease is rel-
atively rare. Instead, most HIV-1 isolates that appear to 
prefer CXCR4 for host cell entry still retain the ability to 
infect CD4+/CCR5+ cells.
In previous studies, we performed hundreds of competi-
tions between HIV-1 isolates of all group M subtypes with 
a focus of subtype C strains [38–40]. Subtype C isolates 
were substantially less fit than all other group M isolates 
when competed in head-to-head pair-wise competitions 
in PBMC cultures using a set of r5 and x4 HIV-1 isolates 
[40]. Two subtype C HIV-1 isolates (C19 and C27) capa-
ble of infecting CD4+/CXCR4+ cells were dual tropic 
(i.e. also capable of infecting CD4+/CCR5+ cells). Thus, 
the reduced fitness of at least two of these “x4” subtype C 
isolates may be related to the r5x4 phenotype, especially if 
there was a high proportion of pure r5 HIV-1 isolates in the 
C19 and C27 HIV-1 isolates. In almost all cases, x4 HIV-1 
have faster replication kinetics than r5 HIV-1 isolates when 
performing dual infections of PBMCs [40, 41]. This dual 
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infection is not a “true” competition considering that the 
r5 and x4 viruses likely replicate in different susceptible 
cells within the PBMC population. In this study, we exam-
ined the impact of both the “CXCR4”-using and “CCR5”-
using clones to the replicative fitness of r5x4 HIV-1 isolates 
in CD4+/CCR5+ cells, CD4+/CXCR4+ cells, and in the 
mixed cell population found in PBMCs. We also competed 
the r5x4 HIV-1 isolates against r5 or x4 primary HIV-1 
isolates in the presence of AMD3100 (CXCR4 antagonist) 
or MVC (CCR5 antagonist) to further confirm relative fit-
ness of each phenotype in the dual tropic HIV-1 isolates. 
Finally, the contribution of the r5 and x4 component to rep-
licative fitness of the primary HIV-1 isolates was compared 
to the sum of its parts by characterizing or predicting the 
co-receptor usage of the representative clones in these dual 
tropic virus populations.
Dual tropic and dm viruses are commonly observed 
in HIV infected patients and are frequently responsi-
ble for failure of maraviroc treatment. Treatment failure 
of maraviroc can result from the emergence of resistant 
CCR5 (r5)- using viruses with reduced susceptibility to 
MVC [42–45]. The contribution of the CCR5(r5)- and 
CXCR4(x4)-using component of the intrapatient HIV-1 
population to overall virus replication in susceptible cells 
is poorly understood. Each component of the dual tropic 
and dm virus can replicate in different T cell and mac-
rophage subsets. In this study, we have determined the 
contribution of the r5-using and x4-using components of 
dm and dual tropic HIV on replicative fitness and deter-
mine if a specific phenotype may be dominant in disease.
Results
Identification of dual tropic HIV‑1 isolates from patient 
samples
Two methods were employed to isolate HIV-1 from 
patient samples and then screen for viral tropism. The 
first method involved initial co-cultivation of PBMCs 
from an HIV-infected patient with PBMCs from an HIV-
negative donor (Fig.  1a). These standard co-cultivations 
were performed on a set of patient samples from Zim-
babwe as previously described [40]. This initial analy-
sis screened over 28 HIV-1 isolates and found 10 that 
were syncytium inducing (SI) and capable of replicating 
on MT2 cells [46]. These primary SI HIV-1 were then 
equalized for RT activity (see “Methods”) and added to 
U87.CD4 cells expressing either CCR5 or CXCR4 [40] 
(Fig.  1b). Two (C19 and C27) of 10 primary HIV-1 iso-
lates were dual tropic, i.e. capable of infecting and rep-
licating in U87.CD4 cells expressing either CXCR4 or 
CCR5 as a co-receptor. HIV-1 C23 showed CCR5 (r5) 
just above the limit of detection whereas the remain-
ing strains in this cohort were CXCR4 (x4) as previously 
described.
As part of another study that screened for co-receptor 
usage, HIV-1 env chimeric viruses were produced by 
homologous recombination in yeast rather than propa-
gating HIV-1 from patient samples (Fig.  1c). The yeast-
based recombination/gap repair cloning method can 
efficiently replace the yeast URA3 gene with the gp120 
coding region of the env gene in our pREC_nfl_HIV-
1NL4-3Δgp120/URA3 vector (see “Methods”) [44, 47]. The 
efficiency of this cloning method limits the genetic bottle-
neck introduced by prolonged PBMC co-cultivation and 
subsequent virus propagations. Following env cloning, 
the pREC_nfl_envPtx vectors from each patient sample 
(Ptx—patient x) were purified from pooled yeast colo-
nies (>1,000) and transfected into 293T cells. We have 
recently described an efficient cell-to-cell fusion assay to 
screen for co-receptor usage using the U87.CD4.CXCR4 
or U87.CD4.CCR5 as target cells [48]. In our preliminary 
screen of 11 patient-derived env chimeric viruses, we 
identified three dual tropic HIV Envs (B9, B12, and B19), 
five r5s, and two x4s (Fig. 1d). The pREC_nfl_env vectors 
of B9, B12, and B19 were co-transfected with the com-
plementing vector (pCMV_cplt) to produce replication-
competent chimeric HIV as described [47]. This virus 
was then used to infect U87.CD4.CXCR4 and U87.CD4.
CCR5 cells to confirm co-receptor usage. HIV-1 env_B9 
did not replicate in either cell line.
The x4 and r5 titers of each dual tropic primary and 
dual tropic env chimeric HIV-1 isolate along with a set 
of reference HIV-1 isolates were measured by standard 
TCID50 assays on U87.CD4.CXCR4 and U87.CD4.CCR5 
cells, respectively (Fig. 1e). The dual tropic C19 and C27 
viruses had equal infectious r5 and x4 titers whereas the 
dual tropic env_B12 and env_B19 viruses had higher r5 
than x4 titers. Interestingly, the infectious titers derived 
from TCID50 assays using HIV-negative PBMCs was the 
same as the highest infectious titers from either U87.
CD4.CXCR4 or U87.CD4.CCR5 cells. For at least the C19 
and C27 viruses, the IU/ml on PBMCs did not reflect the 
simple addition of r5 and x4 infectious units suggesting 
that the clones within these dual tropic HIV-1 isolates 
may be primarily dual tropic rather than a mix of r5- and 
x4-only HIV-1 clones (Additional file 1: Table S1).
Phylogenetic analyses of the dm HIV‑1 isolates and env 
chimeric viruses
Alignment of the env sequences confirmed that the bulk 
populations of the dual tropic C19 and C27 were sub-
type C whereas dual tropic env_B12 and env_B19 aligned 
with other subtype B HIV-1 sequences (Fig. 2a). In addi-
tion, the B12, B19, C19, and C27 viruses were not clonal 
but rather a population of related env sequences, based 
on approximately 10–15 sequenced clones from each 
(Fig. 2b–e).
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Contribution of x4 and r5 variants to replicative fitness 
in dual tropic and mixed r5x4 primary HIV‑1 isolate
In a previous study, we performed two pairwise com-
petition experiments in PBMC cultures with 14 pri-
mary r5 and 15 x4 HIV-1 isolates [40]. The phylogenetic 
relationships of these are shown in Fig. 2. To summarize, 
both the r5 and x4 HIV-1 subtype C isolates were less fit 
than the r5 and x4 HIV-1 isolates (respectively) of dif-
ferent group M subtypes. The poor replicative fitness of 
subtype C isolates has now been observed in over 2,000 
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Fig. 1 Identification of dual/mixed isolates following HIV-1 propagation or construction of env chimeric viruses. a HIV-1 subtype C isolates from 
Zimbabwe were propagated by PBMC co-cultivation as described [46] and in the “Methods”. c The HIV-1 env coding region of HIV-1 subtype B 
infected patients was PCR amplified and then cloned into pREC_nfl_HIV-1nl4-3Δgp120/URA3 via yeast recombination/gap repair [47]. The propa-
gated HIV-1 isolates (a) and cloned env genes expressed following 293T transfection (c) were screened for co-receptor usage by infection(1) (b) 
or cell-to-cell fusion (d) (Veritrop; [48]) on U87.CD4 cells expressing either CXCR4 or CCR5(2). In the virus infection system (b), virus production was 
monitored by RT activity in supernatant [87]. In the cell-to-cell fusion assay (d), the ability of pREC_nfl_envptX to modulate receptor binding and cell 
fusion was monitored by firefly luciferase activity, i.e. Rev/Tat in the effector cell controlling Luc expression under the control of the HIV-1 LTR and 
rescued via the RRE housed in an intron with Luc [80]. Two primary HIV-1 isolates and two env chimeric viruses were propagated to measure infec-
tious titers on PBMCs (Additional file 1: Table S1), U87.CD4.CCR5 and U87.CD4.CXCR4 cells (e) using the classical Reed–Munch approach [79].








































































































































































Fig. 2 Neighbor joining phylogenic trees of two dual tropic HIV-1 isolates, two HIV-1 env chimeric viruses, and of the sampled clones in their virus 
population. Alignments and phylogenetic trees were constructed for the C2-V3 region (350 nt) of the four reference strains, r5 B2, r5 C3, x4 A8, 
and x4 E6, the two dual tropic HIV-1 isolates (C19 and C27), the two HIV-1 env chimeric viruses (B12 and B19) and set of reference strains (a). As 
described in the “Methods”, the Env coding region of two dual/mixed (dm) HIV-1 isolates were PCR amplified and cloned into pREC env via yeast-
based recombination. The C2-V3 sequences from 21 B19 (b), 18 B19 (c), 26 C19 (d), 21 © clones (e) were aligned using MUSCLE and then schematic 
represented in phylogenetic trees.
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head-to-head competitions with over 40 primary subtype 
C HIV-1 isolates [38–40, 49]. Although ten x4 HIV-1 sub-
type C isolates were dramatically less fit than any other 
x4 HIV-1 isolate, we also noted that two isolates, C19 
and C27 were of a dual tropic phenotype and capable of 
infecting both CD4+/CCR5+ and CD4+/CXCR4+ sus-
ceptible cells [40]. When competing r5 against x4 HIV-1 
isolates in PBMCs, the x4 viruses, regardless of subtype, 
had higher replicative fitness than an r5 HIV-1 isolate 
[40]. Thus, it is possible that reduced fitness of dual tropic 
C19 and C27 HIV-1 isolates may have been related to 
high proportion of r5 HIV-1 clones within these viruses.
To determine the relative contribution of the CCR5-
using and CXCR4-using phenotypes in these dual tropic 
r5x4 HIV-1 isolates, the r5x4 C19 and C27 HIV-1 isolates 
were competed against four reference HIV-1 isolates, the 
r5-using B2 and C3 primary isolates and the x4-using A8 
and E6 viruses (Fig. 1e). The control x4 A8 virus is char-
acterized as having a high replicative fitness whereas the 
x4 E6 is of lower replicative fitness when compared in 
direct competition with other x4 isolates [39, 40]. Our 
control r5 B2 virus was also selected based on a higher 
replicative fitness as compared to other r5 HIV-1 isolates 
whereas r5 C3 has low replicative fitness [39, 40]. First, 
the titers of dual tropic C19 and C27 viruses as well as 
control x4 A8 and E6 HIV-1 were calculated using both 
PBMCs (“full” titer) and U87.CD4.CXCR4 (“x4” titer) for 
TCID50 assays (Additional file 1: Table S1).
Direct competitions showed that the dual tropic C19 
and C27 HIV-1 were completely outcompeted by A8 but 
still could compete with the x4 E6 HIV-1 (Fig. 3a), when 
virus inoculums were equalized based on PBMC titers. 
When inoculums were equalized based on x4 titers, the 
fitness of dual tropic C19 and C27 further decreased in 
competition with x4 E6 (Fig. 3a). The dual tropic C19 and 
C27 were then competed in PBMCs against the r5 B2 and 
C3 control viruses using the equalized “full” titers deter-
mined on PBMCs or the equalized “r5” titers determined 
on U87.CD4.CCR5. As observed with nearly all x4-using 
viruses, the dual tropic C19 and C27 HIV-1 isolates were 
more fit than the r5 C3 virus when inoculating with the 
PBMC titers (Fig. 3b). However, dual tropic C19 and C27 
were only slightly more fit than the r5 B2 HIV-1. The 
“CXCR4”-using component of the dual tropic HIV-1 
isolates are not necessarily in competition with these r5 
HIV-1 in PBMC since they likely infect different suscep-
tible cells in the PBMC population. Competitions with 
the control r5 B2 HIV-1 suggest a low frequency of an r5 
phenotype in the dual tropic C19 and C27 viruses. When 
using U87.CD4.CCR5-derived titers, it was not surpris-
ing that C19 and C27 could further out replicate the r5 
B2 and C3 viruses (Fig.  3b) in competition considering 
the fivefold increase in C19 and C27 inocula to equalize 
their “r5” titer with the titer of pure r5 B2 and C3 viruses.
In the competitions performed in PBMC cultures with 
PBMC-derived titers, C19 and C27 could replicate and 
compete with either the r5 (B2 and C3) or the x4 (A8 and 
E6) viruses (Fig. 3). In Fig. 4, we performed the same com-
petitions as in Fig. 3 but prevented replication of either 
the “CXCR4”-using component (panel A) or the “CCR5”-
using component (panel C) of the dual tropic C19 and 
C27 viruses. First, the C19+A8, C19+E6, C27+A8, and 
C27+E6 dual infections were added in equal “x4” titers 
(determined on U87.CD4.CXCR4 cells) to PBMC cul-
tures in the presence of high maraviroc (MVC) concen-
trations. As described in Fig. 4b, the IC99 concentration 
of MVC, a CCR5 antagonist [50, 51], resulted in com-
plete inhibition of the r5 B2 and C3 viruses but no appar-
ent inhibition of C19 and C27 in PBMCs. Lack of C19 
and C27 inhibition by MVC suggests that the majority of 
the HIV-1 clones in these quasispecies may be dual tropic 
(r5/x4) and fully capable of infecting CXCR4+ cells in the 
PBMC cultures such that MVC does not inhibit any virus 
replication. The composition of the quaispecies in terms 
of co-receptor usage is described below (Fig. 1). Interest-
ingly, there was no significant difference in the replicative 
fitness of C19 or C27 (versus control x4 A8 or E6 HIV-
1) when comparing results of competitions performed 
in PBMCs, PBMCs + MVC, or in U87.CD4.CXCR4 cells 
(Fig. 4a). The latter condition would only support repli-
cation of the control x4 viruses and the “CXCR4”-using 
component of the dual tropic viruses. The reference 
viruses A8 and E6 were significantly more fit than the 
“CXCR4”-using component of the dual tropic C19 and 
C27 viruses regardless of the above conditions (Fig. 3a).
To limit replication to only the “CCR5”-using compo-
nent of the dual tropic viruses, we performed competi-
tions in PBMCs + AMD3100 or in U87.CD4.CCR5 cell 
cultures with the “r5” titers of these viruses. AMD3100, 
a CXCR4 antagonist [52, 53], showed strong inhibition 
of x4 A8 and E6 viruses as well as the dual tropic C19 
and C27 viruses whereas the r5 B2 and C3 viruses were 
largely unaffected (Fig. 4d). Reduction in B2 and C3 rep-
lication, as compared to no-drug controls, relates to the 
cellular toxicity from high AMD3100 concentrations, 
i.e. required for complete inhibition of x4 virus replica-
tion but this did not have an effect on the competition 
experiments as later shown with the B12 and B19 viruses. 
Whereas the dual tropic C19 and C27 could easily out 
replicate the r5 B2 and C3 viruses in PBMC cultures, the 
“CCR5”-using component of these viruses were signifi-
cantly less fit than B2 and C3 (Fig. 4c). This data is con-
sistent with the relatively weak fitness of r5 subtype C 
HIV-1 isolates [38–40, 49]. Again these were based only 
Page 7 of 19Nankya et al. AIDS Res Ther  (2015) 12:34 
on the r5 phenotype present as r5 or r5/x4 clones in the 
quasispecies in C19 and C27. Thus, use of AMD3100 
with PBMCs or U87.CD4.CCR5 cells would limit repli-
cation to only the CCR5-using and r5/x4 components 
on CCR5+ cells. In PBMCs (without drug) where the 
“CXCR4” component was not inhibited, the C19 and C27 
were 50- to 100-fold more fit than the r5 B2 and C3 con-
trols. After eliminating replication of the pure CXCR4-
component with AMD3100, the r5 competitors, B2 and 
C3 were now significantly more fit than the “CCR5”-
using phenotype of the dual tropic C19 and C27 viruses 
(Fig. 4c). The 10,000-fold shift in fitness when inhibiting 
the “CXCR4”-using component of the primary C19 and 
C27 isolates (Fig. 4c) would suggest that the majority of 
these dual mixed virus populations were comprised of 
dual tropic clones (e.g. clones that use either CXCR4 or 
CCR5 for entry, thus r5x4) and that the “CXCR4”-using 
phenotype (in absence of inhibition) was dominant in 
determining fitness.
Co‑receptor usage of the C19 and C27 quasispecies
The predicted amino acid sequences of the V3 loop of 
each C19 and C27 clone (Fig.  2) were aligned and then 
used in various algorithms to predict co-receptor usage. 
Based on the C27 consensus sequence, five “groups” of 
C19 clones were identified based on a unique V3 loop 
amino acid profile (Additional file 1: Fig. S1). There were 
three “groups” of clones in the C27 isolate. The five C19 
groups all had Ser and Lys at position 11 and 25 and were 
predicted x4 by the 11/25 rule (positive charge at either 
or both sites) whereas two neutral amino acids, G11 
and A25 predicted a pure r5 phenotype in all of the C27 
clones (Additional file  1: Fig.  S1). Using the PSSM [54], 
Geno2Pheno algorithms [25], and PhenoSeq [55], all C19 
and C27 clones were predicted to use at least CXCR4 for 
entry and that CXCR4-using clones may dominate the 
virus population (PSSM predicted a possible dual tro-
pism) (Additional file 1: Fig. S1).
The predicted co-receptor usage was then compared 
to actual co-receptor usage of the HIV-1 clones from 
C19 and C27. The HIV-1 Env genes sequenced in Fig. 2a 
and used for co-receptor prediction in Additional file 1: 
Fig. S1, were introduced into pREC_nfl_HIV-1nl4-3Δenv/
URA3 via yeast-based recombination and described 
above [42]. This Env expression vector was then used to 
pseudotype virus produced from 293T cells co-trans-
fected with the pNL luc-AM vector [56]. Equal virus 
titers (based on RT activity) were used to infect U87.CD4 
cells expressing either CCR5 or CXCR4. Three (C19-14, 
C19-30, and C19-29) of 26 C19 clones and 2 of 20 C27 
env clones were non-functional. Of the functional clones, 
none of the C19 or C27 clones were purely CCR5 tropic 
whereas several clones were “pure” CXCR4-using, i.e. 
C19-17, -28, -10, -25 (Fig.  5c) and C27-7, -21, -8, -26 
(Fig. 5d).
For these analyses, we sequenced approximately 500 nt 
for each clone and identified 15 unique C19 Env sequence 
patterns, five of these were described as “groups” I–V 
(Fig. 5a). Eleven unique sequences and four “groups” (I–
IV) were identified in the C27 HIV-1 isolates (Fig. 5b). In 
general, the clones within the same group (sharing the 
same C2-V3 nt sequence) showed similar co-receptor 
usage profiles (compare Fig.  5a with c; b with d). How-
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Fig. 3 Relative replicative fitness of the dual tropic C19 and C27 
HIV-1 when competed against reference strains on PBMCs. a The 
dual tropic HIV-1 isolates, C19 and C27 were competed against the 
x4 reference strains, A8 and E6 on PBMC using equal MOIs (0.004) of 
each virus tittered on U87.CD4.CXCR4 cells or PBMCs (same donor 
and blood draw as those used in competition). b A similar set of com-
petitions on PBMCs involved the same dm viruses competed against 
the r5 reference strains, B2 and C3 using equal MOIs tittered on U87.
CD4.CCR5 cells or PBMCs. Fitness difference (or ratio) is shown with all 
competitions where the relative fitness of the dual tropic HIV-1 isolate 
is plotted as a ratio to the relative fitness of the reference virus in the 
competition. The titers of all dual tropic and reference HIV-1 isolates 
are shown in Additional file 1: Table S1.
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I, C19-17 and C19-28 appeared to be pure x4 tropic 
whereas clones C19-11, -20, and -24 could infect both 
CCR5 and CXCR4 expressing cells (r5x4). It is important 
to note that clones that share sequence identity in the 
C2-V3 region may still differ in the remaining ~2,200 nt 
of Env (not sequenced), specifically in the V1V2 region 
which has been shown to influence co-receptor usage. 
Nonetheless, similar co-receptor usage was observed for 
most clones that share at least the C2-V3 sequences.
Finally, we compared five assays to determine co-
receptor usage of these primary isolates: (1) the relative 
infection by primary C19 and C27 HIV-1 isolate on U87.
CD4.CCR5 cells and U87.CD4.CXCR4 cells (Fig.  1c, d), 
(2) the TCID50 values derived on CCR5+ and CXCR4+ 
cells, (3) the relative inhibition by AMD3100 and MVC 
on PBMCs (Fig.  4b, d), (4) predicted co-receptor usage 
from the clones (Additional file  1: Fig.  S1), and (5) the 
actual co-receptor usage of Env clones in the quasispe-
cies (Fig. 5c, d). For these two dual tropic HIV-1 isolates, 
the vast majority of clones in the quasispecies were used 
both R5 and X4 co-receptors. As discussed below, the use 
of co-receptor antagonist coupled with the TCID50 meas-
urements on U87.CD4.CCR5 cells and U87.CD4.CXCR4 
cells provides the best prediction of the co-receptor usage 
within the HIV-1 quasispecies. The C19 and C27 primary 
HIV-1 isolates achieved a dual/mixed phenotype through 
similar quasispecies compositions. Both had more clones 
using both co-receptors, very few using only CXCR4, and 
no pure r5 clones (Fig. 5c, d). As described in our fitness 
analyses, the CXCR4 usage phenotype of a dual tropic 
virus is largely dominant in replicative fitness such that 
when it is inhibited, there is a total loss in fitness of these 
isolates.
Contribution of the CXCR4 and CCR5 using variants 
to replicative fitness in env chimeric viruses
Predominance of the x4 and r5x4 clones in the C19 and 
C27 primary HIV-1 isolates may be related to inability 
of r5 clones to compete during propagation of these pri-
mary HIV-1 isolates (as previously described; [57]). As 
described above, we also identified two patients infected 
with dual tropic HIV-1 through env chimeric virus con-
struction [42]. By this method, there is no propagation 
to result in selection. Bias in the HIV-1 env quasispecies 
composition could be introduced during PCR and clon-




































































































Fig. 4 Fitness of the dual tropic HIV-1 isolate when blocking the virus component using CCR5 or CXCR4. a The primary dual tropic HIV-1 isolates 
were competed against the x4 [50] titereds (all titered on U87.CD4.CXCR4 cells) in U87.CD4.CXCR4 cultures or in PHA-stimulated, IL-2 treated PBMC 
cultures with or without maraviroc. The fitness differences are plotted as described in Fig. 2 and in the “Methods”. b The level of maraviroc inhibition 
of the monoinfections or dual infections was measured by relative RT activity in the cell free supernatant and plotted as a percentage of the no 
drug control. c The primary dual tropic HIV-1 isolates and r5 reference strains were also titered on U87.CD4.CCR5 cells and then competed together 
in PHA-stimulated, IL-2 treated PBMC cultures with or without AMD3100. The same dual infection with the same MOI (0.004) was repeated in U87.
CD4.CCR5 cultures. The fitness differences are plotted as described in Fig. 2 and “Methods”. d The level of AMD3100 inhibition of the monoinfections 
or dual infections was measured by relative RT activity in the cell free supernatant and plotted as a percentage of the no drug control. All experi-
ments were performed in triplicate with the exception of c, d (performed in duplicate) due to limited supply of AMD3100.
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recombination on the HIV-1 genome were conserved for 
all HIV-1 strains [47]. In contrast to the C19 and C27 pri-
mary isolates, the B12 and B29 env chimeric viruses had 
higher r5 than x4 titers (Fig. 1e). Thus, there were mini-
mal adjustments for equal “r5” titers and relative fitness 
of B12 and B19 env chimeric viruses were similar to B2 
and C3. AMD3100 had minimal inhibition of B12 and 
B19 (adjusted for equal r5 titers) (Fig.  6d), which was 
expected based on the low x4-using component in the 
viral populations. The inhibition of “CXCR4”-using com-
ponent (with AMD3100) (Fig. 6c) resulted in only a slight 
reduction in replicative fitness of the dual tropic B12 and 
B19 env chimeric viruses. This 2- to 10-fold decreased fit-
ness in B12 and B19 with AMD3100 treatment was mini-
mal compared to 10,000-fold loss in C19 and C27 fitness 
under the same conditions.
Due to the low “CXCR4”-using component levels in 
the B19 virus, equalizing x4 titers required the addi-
tion of >1,000-fold more volume of B19 (compared to 
B12) in competition with x4 control strains A8 and E6. 
Even with this high concentration of B19 virus over the 
A8 and E6 viruses, the B19 had only slightly greater fit-
ness than A8 and equal fitness to E6 viruses whereas the 
B12 virus was slightly more fit than both A8 (by tenfold) 
and E6 (by threefold) in PBMCs (Fig.  6a). Inhibition 
by MVC appeared to be masked by very high levels of 
virus needed to reach equalized titers of the “CXCR4”-
using component (Fig. 6b). This r5 HIV-1 concentration 
likely saturated the susceptible CCR5+/CD4+  cells in 
the PBMC culture. Nonetheless, some inhibition of the 
more abundant “CCR5”-using component in the B12 
and B19 viruses did reduce the overall fitness of B12 and 
C19-2 GTGPCNNVSTVQCTHGIKPVISTQLLLNGSLSEEGIIIRSENLTNNAKTIIVQLNKSIDIVCTRPSNNTRKSARIGVGPGQAFYAIKKMIGDIRQAHCNISKANWSETLQGVRNKLQGHFPNKSINFEPSSGG
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Fig. 5 Determining the co-receptor usage of C19 and C27 Env clones introduced into HIV-1 NL4-3 backbone via yeast-based recombination. The 
26 C19 and 21 C27 env regions (same as those sequenced for Fig. 1) were cloned into pREC_env/URA3 via yeast-based recombination/gap repair 
[81, 82]. A 132 and 118 amino acid sequence of the C2-V3 region was used to group the C19 (a) and C27 (b) based on sequence identity/difference. 
The pREC_env expression vector was then used to pseudotype virus produced from 293T cells co-transfected with the pNL luc-AM vector [56]. 
Equal virus titers (based on RT activity) were used to infect U87.CD4 cells expressing either CCR5 or CXCR4. The infecting virus is reverse transcribed 
and integrated to express luciferase but is incapable of subsequent rounds of infection [56]. Luciferase activity (relative light units) was measured 
from lysed cells collected 72 h post infection with both the C19 (c) and C27 (d) Env pseudotyped virus infections. All assays were performed in tripli-
cate. Background was subtracted from results and dotted lines on c, d represent the value three times the standard deviation of the background.
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B19 viruses compared to the A8 and E6 viruses (Fig. 6a). 
By reducing the MVC concentration, the B12 and B19 
viruses regained fitness which again suggests that the 
“CCR5”-using component is contributing to the relative 
production of B12 and B19 in these competitions.
Prediction of low level x4 usage
With the B12 and B19 primary HIV-1 isolates, use of the 
co-receptor antagonists coupled with the TCID50 meas-
urements on U87.CD4.CCR5 cells and U87.CD4.CXCR4 
cells provided the best prediction of co-receptor usage 
within the HIV-1 quasispecies. Thus, the x4-using or 
r5x4 component of the B12 and B19 chimeric env viruses 
was less than 1 and 0.1  % of the r5-using component, 
respectively. Based on the estimated low frequency of x4 
or r5x4 clones, phenotypic analyses of co-receptor usage 
would require the cloning and analysis of >100 clones for 
B12 and >1,000 B19 clones (Table  1a, b) to identify r5 
clones. Instead, we compared the predicted co-receptor 
usage for the B19 HIV-1 population found in: (1) env RT-
PCR product from the original patient plasma sample, 
(2) in the pREC_nfl_envB12 plasmid population follow-
ing yeast-based cloning of the B19 env PCR product, and 
(3) in the HIV-1 envB12 chimeric virus populations pro-
duced from 293T cells co-transfected with the pREC_nfl_
envB12 +  pCMV_cplt (see [42] for methods). The viral 
load in the B12 and B19 plasma samples was >50,000 
copies/ml. Over 5,000 copies of RNA (from plasma and 
env chimeric virus) was reverse transcribed and then 
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Fig. 6 Fitness of the dual tropic env chimeric virus when blocking the virus component using CCR5 or CXCR4. a The dm env chimeric viruses (B12 
and B19) were competed against the x4 reference viruses (all titered on U87.CD4.CXCR4 cells) in U87.CD4.CXCR4 cultures or in PHA-stimulated, IL-2 
treated PBMC cultures with or without maraviroc. The fitness differences are plotted as described in Fig. 2 and “Methods”. b The level of maraviroc 
inhibition of the monoinfections or dual infections was measured by relative RT activity in the cell free supernatant and plotted as a percentage of 
the no drug control. c The env chimeric HIV-1 and r5 reference strains (B2 and C3) were titered on U87.CD4.CCR5 cells and then competed together 
in PHA-stimulated, IL-2 treated PBMC cultures with or without AMD3100. The same dual infection with the same MOI (0.004) was repeated in U87.
CD4.CCR5 cultures. The fitness differences are plotted as described in Fig. 2 and “Methods”. d The level of AMD3100 inhibition of the monoinfections 
or dual infections was measured by relative RT activity in the cell free supernatant and plotted as a percentage of the no drug control. All experi-
ments were performed in triplicate with the exception of c, d (performed in duplicate) due to limited supply Of AMD3100.
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Table 1 Determination of predicted co-receptor usage in the HIV-1 isolate by 454 deep sequencing analyses
Italics values indicate clones with different amino acids at the 11/25 positions
a The C2-V3 coding regions was RT-PCR amplified with barcoded 454 primers from the plasma RNA (only for B12), from the plasmid population following yeast 
recombination (no RT step), and from RNA of culture supernatant. Amino acid alignments grouped identical clones. Predictive co-receptor algorithms, 11/25, PSSM, 
and Geno2Pheno were run on the V3 loop amino acid sequences. FPR false positive rate for Geno2Pheno at 5 %.
Culture N Plasmid N Plasma N Genotype PSSM results Geno2Pheno (5 %)
11/25 Prediction % X4 % R5 Prediction FPR (%) Prediction
Predicted co-receptor usage for B19 clonesa
 B19 C1 4,070 B19 P1 4,102 B19 R1 2,237 S/E CCR5 0.11 0.62 CCR5 only 33.90 CCR5
 B19 C2 25 S/E CCR5 0.11 0.59 CCR5 only 10.90 CCR5
 B19 C3 5 S/E CCR5 0 0.1 CCR5 only 55 CCR5
 B19 C4 3 S/E CCR5 0.22 0.82 CCR5 only 41.20 CCR5
B19 P2 3 S/E CCR5 0.22 0.89 CCR5 only 50.50 CCR5
B19 R2 51 S/K CXCR4 0.24 0.92 CCR5 only 7.80 CCR5
B19 R3 13 S/E CCR5 0.22 0.86 CCR5 only 26.90 CCR5
B19 R4 11 S/E CCR5 0.11 0.42 CCR5 only 72 CCR5
B19 R5 7 S/E CCR5 0.11 0.46 CCR5 only 47.70 CCR5
B19 R6 7 S/E CCR5 0.11 0.46 CCR5 only 47.70 CCR5
B19 R7 6 S/E CCR5 0.11 0.46 CCR5 only 47.70 CCR5
B19 R8 6 S/E CCR5 0.11 0.46 CCR5 only 47.70 CCR5
B19 R9 6 S/E CCR5 0.11 0.46 CCR5 only 47.70 CCR5
B19 R10 5 S/E CCR5 0.11 0.6 CCR5 only 42.30 CCR5
B19 R11 4 S/E CCR5 0.11 0.47 CCR5 only 18.20 CCR5
B19 R12 4 S/E CCR5 0.09 0.39 CCR5 only 59.80 CCR5
B19 R13 3 S/E CCR5 0.11 0.46 CCR5 only 47.70 CCR5
B19 R14 3 S/K CXCR4 0.29 0.95 CXCR4 capable 3.20 CXCR4
Plasmid N Culture N Genotype PSSM Results Geno2Pheno (5 %)
11/25 Prediction % X4 % R5 Prediction FPR (%) Prediction
Predicted co-receptor usage for B12 clonesa
 B12_P1 3,611 B12_C1 1,405 S/Q CCR5 0.31 0.96 CCR5 only 20.40 CCR5
 B12_P2 55 B12_C2 19 S/Q CCR5 0.31 0.96 CCR5 only 20.40 CCR5
 B12_P3 24 B12_C3 10 S/Q CCR5 0.31 0.96 CCR5 only 20.4 CCR5
 B12_P4 21 B12_C4 6 S/Q CCR5 0.27 0.95 CCR5 only 18.80 CCR5
B12_C5 6 S/Q CCR5 0.33 0.96 CCR5 only 22.60 CCR5
B12_C6 6 S/Q CCR5 0.31 0.96 CCR5 only 20.40 CCR5
B12_C7 5 S/Q CCR5 0.36 0.98 CCR5 only 10.50 CCR5
B12_C8 5 S/Q CCR5 0.36 0.98 CCR5 only 17.10 CCR5
 B12_P10 3 B12_C9 5 S/Q CCR5 0.33 0.96 CCR5 only 20.20 CCR5
 B12_P17 3 B12_C10 4 S/Q CCR5 0.31 0.96 CCR5 only 20.40 CCR5
B12_C11 4 S/Q CCR5 0.47 0.98 CCR5 only 36.90 CCR5
 B12_P15 3 B12_C12 3 S/Q CCR5 0.31 0.96 CCR5 only 20.40 CCR5
B12_C13 3 S/Q CCR5 0.51 0.98 CCR5 only 35.60 CCR5
 B12_P8 4 B12_C14 3 S/Q CCR5 0.33 0.96 CCR5 only 49.70 CCR5
B12_C5 3 S/Q CCR5 0.33 0.98 CCR5 only 14.40 CCR5
 B12_P5 7 B12_C1 1,405 S/Q CCR5 0.31 0.96 CCR5 only 20.40 CCR5
 B12_P6 6 B12_C2 19 S/K CXCR4 0.53 0.99 CXCR4 capable 4.80 CXCR4
 B12_P7 4 B12_C3 10 S/E CCR5 0.36 0.98 CCR5 only 1.70 CXCR4
 B12_P9 3 B12_C4 6 S/Q CCR5 0.29 0.95 CCR5 only 13.10 CCR5
 B12_P11 3 B12_C5 6 S/Q CCR5 0.31 0.96 CCR5 only 20.40 CCR5
 B12_P12 3 B12_C6 6 S/Q CCR5 0.42 0.98 CCR5 only 6.80 CCR5
 B12_P13 3 B12_C7 5 S/Q CCR5 0.31 0.96 CCR5 only 17.80 CCR5
 B12_P14 3 B12_C8 5 S/Q CCR5 0.33 0.96 CCR5 only 7.90 CCR5
 B12_P16 3 B12_C9 5 S/Q CCR5 0.29 0.95 CCR5 only 8.20 CCR5
 B12_P18 3 B12_C10 4 S/Q CCR5 0.51 0.98 CCR5 only 6.80 CCR5
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V3 loop as described in the “Methods”. Over 100,000 cop-
ies of DNA plasmid was sampled for 454. Unfortunately, 
the RT-PCR products of the B19 plasma sample (58,000 
copies/ml) were unavailable for these analyses. An aver-
age depth of ~1,500–4,000 reads were obtained per sam-
ple. Only 105 nt of the V3 loop were analyzed and used 
to predict co-receptor usage based on 11/25 rule, subtype 
specific PSSM, Geno2Pheno (G2P, with a 5 % FPR), and 
PhenoSeq (Table 1a, b). For B19 plasma sample, 95 % of 
the 2,363 V3 reads were identical and predicted to be r5 
by all three algorithms. Approximately 2  % of the reads 
(N = 51) had Lys at amino acid position 25 in the V3 loop 
and were predicted by PSSM and G2P to be x4 (Table 1a). 
Consistent with the low titers of x4 versus r5 in this B19 
env chimeric virus (<0.1  %), we could not detect an x4 
clone in ~4,100 V3 reads from the plasmid or the result-
ing virus. For B12 env chimeric virus, 10 clones (0.3  %) 
were predicted as x4 using by G2P but only 6 of these car-
ried Lys at position 25 and were x4 using based on PSSM 
(Table 1b). Again, the percentage of predicted x4 or dual 
tropic clones in the B12 chimeric virus population was 
consistent with the relative x4 and r5 titers (Fig. 1e).
Discussion
HIV-1 disease progression is associated with the appear-
ance of viral variants that are able to use an expanded 
repertoire of co-receptors for cell entry. Three phe-
notypes of HIV-1 isolates have been described: the r5 
isolates that are more frequently transmitted and also 
predominate during the asymptomatic period of infec-
tion, the x4 variants that predominate in about 50  % of 
the infected individuals in the late phase of infection, 
dm and dual tropic isolates that could represent a tran-
sitional phenotype from r5 to x4. The x4, dual tropic and 
dm viruses have been associated with rapid CD4 declines 
and progression to AIDS and death but the prevalence/
appearance of x4, dm and dual tropic HIV-1 was origi-
nally described for subtype B infections [28–31, 36]. A 
switch to an x4 or dual tropic phenotype in HIV-1 sub-
type C infections is quite infrequent [58] whereas sub-
type D HIV-1 infections have much higher prevalence of 
x4/dual tropic viruses, which also appear earlier in dis-
ease [59, 60]. However, Johnston et  al. [61] screened 28 
subtype C patients and 20 of these were found to be x4 
or dual tropic. The high x4/dual tropism in this cohort 
was attributed to the fact that all these patients had been 
on antiretroviral therapy and for most of them, there was 
evidence of resistance. It is also important to note that the 
propagation of primary HIV-1 isolates on PHA-activated 
PBMCs commonly enriches for CXCR4-using virus even 
in HIV-1 populations with a low frequency x4 compared 
to r5 variants [57]. Early studies on HIV-1 tropism which 
defined the syncytia inducing (SI) and non-SI phenotypes 
relied on propagation which may have favored replication 
of the SI, T cell tropic HIV-1 clones (now defined as x4).
The rate of x4, dm or dual tropic HIV-1 outgrowth dur-
ing propagations from patient samples typically depends 
on both the replicative fitness of x4 and r5 HIV-1 clones. 
This replicative fitness may also be one of many variables 
contributing to the appearance of x4 viruses during dis-
ease progression. As described earlier, other factors may 
include availability of target cells, co-receptor expression 
on susceptible cell subsets, differential immune response 
to x4 and r5 viruses, and preferential transmission of 
r5 variants followed by a slow evolution to x4 virus. 
Increased “in vivo” fitness of r5 HIV-1 variants over low 
frequency x4 variants in the intrapatient HIV-1 popula-
tion is quite apparent based on various MVC treatment 
studies [62, 63]. Treatment failure of maraviroc can result 
from the emergence of resistant CCR5 (r5)-using viruses 
with reduced susceptibility to MVC [42–45]. However, 
the most common escape pathway for MVC resistance 
relates to the outgrowth of the intrinsically resistant x4 
variants in a treated individual. In almost all cases, the 
x4 virus was found within the quasispecies prior to the 
treatment and often at a frequency requiring sensitive 
phenotypic or genotypic assays for detection [62, 63]. In 
the environment of MVC treatment, x4 emerged due to 
increased fitness over r5 and possibly dual tropic viruses 
in the intrapatient HIV-1 population. Based on these 
findings, the relative contribution of r5 and x4 virus com-
ponents to the overall fitness of a primary isolate as well 
as the emergence of dual tropic HIV-1 isolate may have 
important implications on subsequent disease progres-
sion or response to MVC treatment.
In this study, we have measured the ex  vivo replica-
tive fitness of two dual tropic subtype C HIV-1 isolates 
and two dual tropic env chimeric viruses under differ-
ent conditions. In our previous studies on replicative fit-
ness involving pairwise competitions in PBMCs, it was 
important to standardize the initial virus inoculums via 
infectious titers, commonly calculated as TCID50 values 
determined with PBMCs from the same donor and blood 
draw as those used in the competitions [57, 64]. Subse-
quent dual infections with two equal inocula of viruses 
of the same phenotype (i.e. r5 vs. r5 viruses or x4 vs. x4 
viruses) will then compete for the same susceptible cell 
population within PBMCs. When dual infections are 
performed with an r5 and x4 virus, the viruses do not 
necessarily compete since they replicate in different cell 
populations within PBMCs and yet, the x4 viruses almost 
always replicate with faster kinetics to dominate the cul-
tures simply because they have a stronger pathogenic 
phenotype [41, 57]. Thus, we wanted to assess the rela-
tive contribution of the CXCR4 and CCR5 components 
to the replicative fitness of dual tropic HIV-1 strains. We 
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first screened for dual tropism in a collection of primary 
HIV-1 isolates and in env chimeric HIV-1 isolates con-
structed from patient plasma samples. We obtained two 
dual tropic primary HIV-1 isolates (C19 and C27) and 
two dual tropic env chimeric virus constructs (B12 and 
B19).
Co-cultivation of HIV + PBMCs with PBMCs derived 
from HIV-negative donors is a common method to 
obtain primary HIV-1 isolates. Several studies have indi-
cated that x4 or dual tropic clones can expand more rap-
idly than r5 clones [57, 65]. As a consequence, x4 clones 
may predominate the primary HIV-1 isolates even if the 
original HIV-1 quasispecies in the patient PBMCs had 
very low frequency of x4 versus r5 clones. When we 
have examined the x4 frequency in several primary dual 
tropic HIV-1 isolates, the x4 or r5x4 clones typically pre-
dominate the quasispecies (as with C19 and C27) [57]. 
Because of this selection bias during virus propagation, 
we now clone the env gene from patient samples into a 
plasmid with the HIV-1 NL4-3 backbone and then pro-
duce virus by direct DNA transfection. Typical bacterial 
cloning of ~3 kbp fragment into a ~8 kbp DNA vector is 
quite inefficient, produces few bacterial colonies contain-
ing the plasmid with insert, and results in an undesired, 
severe genetic bottleneck on the HIV-1 env quasispecies. 
As previously described, cloning of this env product into 
the pREC_nfl_HIV-1NL4-3Δgp120/URA3 construct via 
yeast homologous recombination/gap repair results in 
thousands of yeast colonies and a minimal genetic bottle-
neck in the env quasispecies [47]. Nonetheless, comple-
mentation with the patient-derived gp120 coding region 
(or entire env gene) and the NL4-3 backbone can occa-
sionally result in a “dead” virus [66].
Using the primary HIV-1 isolates and the env chimeric 
viruses for fitness studies, we observed significant differ-
ences that reflected the r5, x4, and r5x4 composition in 
the quasispecies. Both x4r5 and x4 clones were observed 
in C19 and C27 primary HIV-1 isolates (1) as pre-
dicted by co-receptor usage algorithms applied to clonal 
sequencing analyses and (2) as determined by a pheno-
typic co-receptor usage assay applied to HIV-1 clones in 
the quasispecies. Interestingly, the “CXCR4”-using com-
ponent was dominant over the “CCR5”-using component 
in determining replicative fitness of the r5x4 population 
in the C19 and C27 primary isolates (pure x4 clones were 
rare and r5 clones were absent). When the “CXCR4”-
using component was completely inhibited in these pri-
mary HIV-1 isolates, the “CCR5”-using component of the 
r5x4 population could not compete with control r5 HIV-1 
isolates. Interestingly, when competitions were limited to 
the “CCR5”- or “CXCR4”-using component in the pri-
mary r5x4 HIV-1 isolate, the replicative fitness was quite 
similar to related primary r5 and x4 HIV-1 isolates. The 
r5- and x4-using components of the C19 and C27 viruses 
were significantly less fit than the r5 B2 and C3 HIV-1 
isolates or the x4 A8 and E6 HIV-1 isolates, respectively. 
We have published several studies showing that primary 
subtype C HIV-1 isolates are less fit than any other group 
M HIV-1 isolate (determined in head-to-head competi-
tions in PBMCs from multiple donors) [38–40, 49]. It is 
interesting to note that from our unpublished and pub-
lished data, subtype C competes well with other subtypes 
in ex vivo competition in langerhans cells implying that 
the transmission fitness of this subtype is comparable to 
that of other subtypes. However, after entry into cells, 
the pathogenic fitness of subtype C is lower than other 
subtypes, a possible explanation of the dominance of r5 
tropism in subtype C which leads to a slower disease pro-
gression. In general, the less virulent r5 variants are more 
common during late subtype C infection.
Based on previous studies [67, 68] it appears that dual 
tropic isolates may be evolutionary intermediates. The 
early phase of intrapatient HIV-1 evolution consists 
predominantly of r5 variants possibly with a few r5x4 
but likely minimal or no x4 variants [57, 69]. During the 
time of infection and possibly the absence of treatment, 
the r5x4 variants may increase in frequency and pos-
sibly mutate to a pure x4 variant [65, 70, 71]. However, 
previous studies also suggest that these r5x4 and x4 vari-
ants often represent separate lineages from CCR5 vari-
ants with deep roots within the intrapatient phylogenetic 
tree [72]. The actual mutational pathways from a single 
HIV-1 clone that leads to a phenotypic switch from r5 
to x4 may arise with significant cost to replicative fitness 
[73]. These findings imply that this shift in tropism may 
be under selective pressure, i.e. increased availability of 
CXCR4+  versus CCR5+ susceptible cells. In our stud-
ies it appears that the “CXCR4”-using component of the 
r5x4 clones in the C19 and C27 were dominant over the 
“CCR5”-using component in determining replicative fit-
ness. The “CXCR4”-using component of the dual tropic 
C19 and C27 HIV-1 isolates were generally less fit than 
the control x4 A8 and E6 HIV-1 isolates. However, we 
cannot assume that this reduced fitness was due to the 
initial mutation pattern leading to a switch in r5 to x4 
since subtype C HIV are generally less fit than any other 
group M HIV-1 isolate.
The findings with C19 and C27 primary HIV-1 isolates 
might suggest that the “CXCR4”-using component of 
a dual tropic HIV-1 would dominate over the “CCR5”-
using component in replicative fitness. However, this 
finding is misleading for patients harboring mixed X4 
and R5 HIV viruses. As noted earlier, the primary HIV-1 
isolates such as C19 and C27 primarily contain x4 or 
r5x4 clones and only low levels of r5 clones due to selec-
tion during PBMC co-cultivation/propagation. Within 
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patients, x4 or r5x4 HIV-1 are often found at low fre-
quency in the quasispecies. Thus, we constructed the 
B12 and B19 env chimeric viruses from patients with 
mixed X4 and R5 HIV-1. In these viruses, the r5 clones 
were 100- and 1,000-fold more abundant than the x4 or 
r5x4 clones. These findings were confirmed by (1) meas-
uring infectious titers in both U87.CD4.CCR5 cells and 
U87.CD4.CXCR4 cells and by (2) predicting co-receptor 
usage from approximately 1,000–4,000 V3 loop sequence 
reads (derived by 454 pyrosequencing of ~10,000 patient-
derived DNA templates). In the B12 and B19 env chi-
meric viruses, the CCR5 component derived from the 
pure r5 clones did contribute to overall replicative fitness. 
The more dominant “CXCR4” component in the C19 and 
C27 resulted in the ability to compete with the control 
x4 A8 and E6 HIV-1. In contrast, high levels of “CCR5” 
versus the “CXCR4” component in the B12 and B19 env 
chimeric virus resulted in low replicative fitness when 
competed against x4 A8 and E6 HIV-1. In general, x4 
HIV-1 out replicates r5 HIV-1 in PBMC cultures. When 
adjusting for the r5 or x4 titers, the “r5” or “x4” compo-
nents of B12 and B19 HIV-1 had similar fitness and were 
able to compete with the r5 (B2 and C3) and x4 (A8 and 
E6) control strains. These findings are consistent with our 
previous studies in that subtype B x4 or r5 HIV-1 isolates 
have, on average, higher replicative fitness than HIV-1 
isolates from other group M subtypes [38–40].
Previous studies suggest a dominance of the “CXCR4”-
using over the “CCR5”-using phenotype in HIV-1 defined 
as dual tropic/mixed tropic. As a consequence, a pro-
posed x4 dominance in mixed X4 and R5 HIV-1 has 
been implicated in MVC treatment outcome and dis-
ease progression. Again, our findings with the C19 and 
C27 viruses suggest that use of primary HIV-1 isolates 
may over-emphasize this x4 dominance. The x4 or x4r5 
HIV clones are typically dominant within the intrapa-
tient quasispecies of some patients during late infection 
[65, 74]. Otherwise, x4 or x4r5 HIV clones are found at 
low frequencies compared to the pure r5 clones in the 
intrapatient quasispecies during asymptomatic disease. 
Furthermore, “CXCR4”- using HIV isolates are rare in 
subtype A and C [27, 58, 75] but more frequent in sub-
type B and D infected patients [59]. The x4 HIV strains 
typically have faster replication kinetics than r5 HIV but 
due to limited CCR5+/CXCR4+/CD4+  cells in PBMC 
cultures, these two HIV-1 phenotypes are not in direct 
competition in our studies. When we equalize for r5 or 
x4 titers in the dual tropic HIV-1 and limited replication 
to the “CCR5”-using and “CXCR4”-using components, 
we found that fitness of C19 and C27 virus reflected that 
of other subtype C HIV-1 isolates, i.e. less fit than most 
group M HIV-1 isolates. In contrast, even the low level 
of x4 or x4/r5 B12 and B19 HIV-1 had replicative fitness 
comparable to the control x4 viruses. However, without 
adjusting virus titers for the “CXCR4-using” component, 
this low level of x4 HIV-1 had minimal impact on repli-
cative fitness of this env chimeric virus which was domi-
nated by r5 clones. These findings suggest that detection 
of low frequency x4 clones in the HIV-1 quasipecies is 
not necessarily synonymous with rapid HIV replication 
kinetics and faster disease progressions. However, the 
overall replicative fitness in PBMCs regardless of the x4 
and r5 composition remains a strong correlation of dis-
ease progression [41, 57, 76–78].
Conclusions
In this study, we show that x4 component is dominant in 
replicative fitness but is typically of low frequency com-
pared to r5 HIV-1 in most dual tropic HIV-1 quasispe-
cies. Based on findings in this study, the emergence of 
dual/mixed tropic viruses may have important implica-
tions on response to maraviroc containing regimens. Fur-
thermore, although the “CXCR4”-using phenotype is of 
low frequency in the dual/mixed population, it may have 
a selective advantage in patients failing maraviroc. Based 
on our findings that the “CXCR4”-using phenotype is the 
major determinant of replicative fitness, this may have 
important implications on disease progression.
Methods
Cells
293T cells (human embryonic kidney cells) were grown 
on Dulbeco’s Modified Eagle’s medium (DMEM) sup-
plemented with 10 % fetal bovine serum (FBS) (Cellgro), 
100  U/ml of penicillin and 100  μg/ml of streptomycin 
(Cellgro). U87.CD4 (human glioma cells) expressing 
either CCR5 or CXCR4, obtained from the NIH AIDS 
Research and Reference Reagent Program (distributed 
by Dr. D Littman) were maintained in complete DMEM 
medium supplemented with 1 mg/ml of geneticin G418 
(Life Technologies, Inc.) and 5 µg/ml puromycin to main-
tain receptor and coreceptor expression [5]. Peripheral 
blood mononuclear cells (PBMCs) from HIV-negative 
blood donors were obtained by Ficoll-Hypague den-
sity centrifugation of heparin treated venous blood. 
These were stimulated with 2  µg/ml of phytohemagglu-
tinin (PHA; Gibco BRL) and 1  µg/ml of interleukin-2 
(IL-2; Gibco BRL) in complete RPMI 1640 containing 
2 mM l-glutamine for 3–4 days.
Virus propagation, chimeric virus production, and titers
Subtype C syncytium inducing (SI) HIV-1 isolates 
obtained from patients who had been on reverse tran-
scriptase inhibitors for an average of 14.4  months [46] 
as well as the non-SI and SI-using reference viruses [38, 
40] (Table 1) were grown in PHA-activated PBMCs over 
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a period of 2 weeks. RT assays were performed at differ-
ent time points to measure virus production. As deter-
mined by Abraha et al. [40], co-receptor usage was then 
estimated by exposing U87.CD4.CCR5 and CXCR4 cells 
to each virus.
In a subtype B cohort analyses, RNA was extracted 
from plasma samples from 11 untreated, HIV-infected 
patients (investigators were blinded to all patient demo-
graphics). The HIV-1 env gene was then reverse tran-
scribed-PCR amplified from the plasma RNA with the 
Env-End primer as described [44]. The gp120 regions 
were then PCR amplified using primers F_gp120 
(5′-GACAGGTTAATTGATAGACTA-3′) and B_gp120 
(5′-CTTCCTGCTGCTCCCAAGAAC-3′). Briefly, these 
gp120 PCR products were cotransformed with SacII-lin-
earized pREC_NFL_Δgp120/URA3 into Saccharomyces 
cerevisiae MYA-906 cells (ATCC). Following homologous 
recombination, plasmids were extracted from the yeast 
cells and transformed into electro-competent Escherichia 
coli Stbl4 cells (Invitrogen). Individual bacterial colonies 
were grown, and plasmids were extracted using Qiagen 
miniprep kits. The cloning procedures have been exten-
sively described [44, 47]. Of the 11 plasma samples from 
HIV-infected patients, we obtained 3 pREC_nfl_gp120 
vectors harboring a functional HIV-1 env gene from the 
patient. The pREC_nfl_gp120 vectors were then co-trans-
fected into 293T cells along with the complementing vec-
tor, pCMV_cplt to produce infectious virus as described 
[47]. To avoid confusion, we will refer to the viruses with 
an NL4-3 backbone and containing the patient’s gp120 
coding region as env chimeric viruses.
TCID50 determination for all the viruses was per-
formed on PHA/IL-2 stimulated HIV negative donor 
PBMCs as well as on U87.CD4.CCR5 and CXCR4 cells. 
For PBMCs, 100,000 cells were added to each of the wells 
in a 96 well plate. Ten-fold serial dilutions of each virus 
were made and 100 μl were added to each well containing 
the cells with each dilution performed in triplicates [64]. 
The viruses were grown in RPMI-1640 complete media. 
Similar dilutions were made for the U87 cells, 10,000 cells 
per well were plated in 96 well plates in DMEM com-
plete media containing G418 and puromycin 24 h prior 
to infection. At the time of infection, media contain-
ing selection antibiotics was removed and replaced with 
DMEM with no selection. Supernatants were harvested 
at different time points to measure RT activity. TCID50 
for each virus was calculated using the Reed and Muech 
method [79].
Veritrop cell‑to‑cell fusion assay
A new cell fusion assay to measure co-receptor usage to 
a 2 % level has been recently described [48]. Briefly, 2 ug 
of pREC_nfl_envptX is transfected into 293T cells using 
Fugene as described [48]. After 24  h, the transfection 
reagent is removed by cell washing and the 293T cells 
are layered over U87.CD4.CCR5 and CXCR4 cells trans-
fected with pDM1.1 [80]. Luciferase is only produced 
from pDM1.1 in the presence of Tat and Rev derived 
from the 293T cells fused with U87 cells transfected with 
the pREC_nfl vector, i.e. expressing the entire HIV-1 
proteome.
Determination of fitness of the dual tropic isolates
Fitness of the dual tropic isolates was determined on 
both PBMCs and U87.CD4.CCR5 and CXCR4 cells using 
dual competition assays described previously [38–41, 
57]. Briefly, for PBMCs, to determine the effect of the 
“CCR5”-using phenotype on fitness, the dual-tropic iso-
lates were competed against r5-using isolates (C3 and 
B2) at a multiplicity of infection (MOI) of 0.004 in the 
presence or absence of AMD3100, a CXCR4 corecep-
tor antagonist. AMD3100 was used at a concentration of 
0.1 µM (>the inhibitory dose for 99 % inhibition or IC99). 
To determine the role of the “CXCR4”-using phenotype 
in fitness of the dual tropic isolates, the dual-tropic iso-
lates were competed against x4-using isolates (E6 and 
A8) in the presence or absence of maraviroc at an MOI 
of 0.004. Maraviroc was used at a concentration of 1 µM 
(IC99).
On U87 cells, the role of the “CCR5” phenotype on 
fitness of the dual tropic isolates was determined by 
competing the dual tropic isolates against the r5 using 
competitor (B2 and C3) viruses on U87.CD4.CCR5 cells 
at an MOI of 0.004. The same isolates were competed 
against the x4-using competitor viruses (E6 and A8) on 
U87.CD4.CXCR4 cells at an MOI of 0.004. For all the 
competition experiments, mono-infections represent-
ing each of the viruses in the competition were included. 
Virus production was monitored over a period of time 
by measuring RT activity at different time points. At the 
time of peak virus production, the cells were harvested 
and DNA was extracted using the Qiagen DNA extrac-
tion kit.
Determination of viral fitness using heteroduplex tracking 
assay
To determine viral fitness, the env gene was PCR ampli-
fied in the C2-V3 region using a nested PCR. For the first 
round ENV B (5′-AGAAAGAGCAGAAGACAGTG-
GCAATGA) and antisense primer ED 14 (5′-TCTT-
GCCTGGAGCTGTTTGATGCCCCAGAC) were 
used to amplify a 1,400  bp of the env gene. The second 
round PCR was performed using a sense primer E80 
(5′-CCAATTCCCATACATTATTGTG) and an anti-
sense primer E125 (5′-CAATTTCTGGGTCCCCTC-
CTGAGG) amplifying a 480  bp fragment of the C2-V3 
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region. PCR conditions were as described. The PCR 
products were run on a 1 % agarose gel stained with 1 % 
ethidium bromide and viewed under UV illumination. 
C2-V3 fragment amplified from subtypes D and E with 
a 32P labeled E80 and unlabeled E125 primer were used 
as probes. To determine the relative virus production for 
each virus in the competition, a heteroduplex tracking 
assay (HTA) was used as previously described [38–41]. 
Heretoduplexes were separated on a 6 % non-denaturing 
gel and quantified using a Molecular Imager FX (BioRad) 
phosphoimager. Virus production for each of the virus 
in the competition (fo) was divided by the initial propor-
tion in the inoculum (io) to get the relative fitness value 
(w = fo/io) [38–41]. The relative fitness value of each iso-
late in the competition is a measure of the fitness differ-
ence WD between the two HIV-1 variants (WD  = WM/
WL), where WM and WL correspond to the relative fitness 
of the more and less fit virus.
Plasmid generation and env sequencing
The env gene (gp160) was PCR amplified from each of the 
dual-tropic isolates by nested PCR to obtain a 2,750  bp 
fragment. The first round PCR was amplified using Env 
A 5′-GGCTTAGGCATCTCCTATGGCAGGAAGAA 
(5,954–5,982 positions of the HXB2 genome) and Env 
M 5′-TAGCCCTTCCAGTCCCCCCTTTTCTTTTA 
(9,068–9,096). The second round PCR was carried out 
with Kpn-1Env TGTGGGTCACAGTCTATTATGG 
(6,325–6,346) and Env-End 5′-CTTTTTGACCACTT-
GCCACCCAT (8,797–8,819) primers. This PCR prod-
uct was then cloned into a yeast vector by homologous 
recombination as described elsewhere. Briefly, the PCR 
amplified gp160 was cloned into a SacII linearized pREC_
nfl_HIV-1nl4-3env/URA3 vector by homologous recom-
bination as already described [81, 82]. Thirty colonies 
were picked for each of the dual-tropic isolates. For each 
of these, the C2-V3 region was sequenced as described 
above and then analyzed to determine coreceptor 
usage via the 11/25 rule or with the webPSSM [54] and 
Geno2Pheno algorithms [25]. Sequences were aligned 
using ClustalX [83] and MUSCLE [84, 85] followed by 
phylogenetic tree constructions using TreeView [86].
Pyrosequencing of the B12 and B19 env chimeric 
viruses was performed on PCR amplicons of the C2-V3 
region. Nested PCR products for sequencing were gen-
erated using the external products described above as 
templates with custom designed fusion oligos that con-
tained the 454 adaptor sequences (Roche Lib-A Primer 
A and Primer B), followed by a 10 basepair Multiplex 
Identifier (MID) sequence to permit sample pooling, 
and lastly the HIV-1 template specific oligos E110 and 
E125 (5′-CTGTTAAATGGCAGTCTAGCAGAA-3′ and 
5′-CAATTTCTGGGTCCCCTCCTGAGG-3′, respec-
tively). Samples were quantified by fluorometry with 
the Quant-iT PicoGreen dsDNA Assay Kit (Life Tech-
nologies), pooled in equimolar concentrations, and 
sequenced on a 454 GS Junior System (Roche Diagnos-
tics) using the GS Junior Titanium Sequencing chem-
istry. The resulting reads were trimmed to exclude the 
MIDs and primer sequence, and low-quality reads were 
filtered using the GS Run Processor according to length 
and quality scores. Multisequence alignments of reads 
were constructed using MUSCLE (PMID: 15034147), 
and all phylogenetic analysis was performed with 
MEGA5 (PMID: 21546353).
Pseudotyping single cycle assays
The pNL luc-AM vector described by Pugach et  al. [56] 
was cotransfected along with one of each pREC env clonal 
plasmid (thirty for each dual tropic isolate) into 293T cells 
using effectene transfection kit (Qiagen, Valencia, CA, 
USA). Pseudovirus-containing supernatants were har-
vested from each well at 72 h post transfection and then 
used to infect both U87.CD4.CCR5 and U87.CD4.CXCR4 
cells in triplicate. After 72 h at 37°C in 5 % CO2, the super-
natant was removed and cells were washed with 200 μl of 
phosphate buffered saline (PBS, Cellgro). 100 µl of cellgro 
lysis buffer was added to lyse the cells. 50 µl of the Lucif-
erin Steady Glo substrate was added to 50  µl of lysate 
supernatant to measure luciferase activity.
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